vimarsana.com
Home
Live Updates
Enzyvant Receives FDA Approval for RETHYMIC® (allogenei
Enzyvant Receives FDA Approval for RETHYMIC® (allogenei
Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic
RETHYMIC is the first and only FDA-approved treatment indicated for immune reconstitution in pediatric patients with congenital athymia Children with...
Related Keywords
Cambridge ,
Cambridgeshire ,
United Kingdom ,
United States ,
Switzerland ,
Louise Markert ,
Rachelle Jacques ,
Duke University School Of Medicine ,
Rare Pediatric Disease Program ,
European Medicines Agency ,
Drug Administration ,
Duke University School ,
Priority Review Voucher ,
Rare Pediatric Disease ,
Review Board ,
Efficacy Analysis Set ,
Safety Analysis ,
Regenerative Medicine Advanced Therapy ,
Breakthrough Therapy ,
Orphan Drug ,
Advanced Therapy Medicinal Product ,
Safety Information ,
Enzyvant ,